Cardiovascular Research · 13 Nov 2026
Oxidized LDL pathophysiology and potential as a therapeutic target in atherosclerosis
Jan Nilssonh-index 25, Todd C Villines, Peter Libbyh-index 53, Göran K Hansson
Citations by database
Each database indexes a different set of journals, preprints and books, so they are shown side by side rather than blended.
- OpenCitations0
- Crossref0
- Europe PMC0
Citations per year
The current year is still counting.
- 2026 so far0
Abstract
Abstract Uptake of oxidized and other forms of modified low-density lipoprotein (LDL) drives formation of foam cells, a hallmark of atherosclerotic plaques. Experimental studies demonstrating the proinflammatory and cytotoxic properties of oxidized LDL have led to the concept of LDL oxidation as one key factor in both development and destabilization of atherosclerotic plaques. Such data positioned oxidized LDL as a promising target for prevention or mitigation of atherosclerotic cardiovascular disease. Yet the failure of multiple antioxidants to reduce cardiovascular risk in large randomized clinical trials has hampered this prospect. Such null studies have stimulated interest in an alternative approach: the therapeutic potential of antibodies against oxidized LDL. High levels of IgM against oxidized LDL phospholipids are associated with lower cardiovascular risk and these antibodies function primarily through neutralization and stimulation of clearance of modified LDL. IgG antibodies against aldehyde-modified peptide sequences in apolipoprotein B-100, the signature protein component of LDL, are also associated with lower risk of cardiovascular disease but experimental studies have shown that these antibodies function by locally forming immune complexes with oxidized LDL that limit the inflammatory activity of certain plaque macrophages. A phase 2 pilot study showed that one such antibody, orticumab, reduces an imaging index of local coronary arterial inflammation in patients with psoriasis. Thus, emerging evidence supports the possibility of using oxidized LDL antibodies to limit atherothrombotic disease.
What the data shows
- No database records a citation yet, as is usual for a paper this new.
- Peter Libby has the highest h-index among the authors (53).
Graph
This paper in the middle, its authors and their most-cited papers below, the papers it cites to the left and the papers citing it to the right. The timeline lays every paper out by year.
Select a node for its details. Drag to pan, scroll to zoom, drag a node to move it.
Start with
Cited by 0 papers
Who cites this paper, from open citation data, with Crossref's record of each; the 100 newest when there are more.
References (0)
What it cites, from open citation data, with Crossref's record of each.